Friday - April 17, 2026

Renal Cell Carcinoma Treatment Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Renal Cell Carcinoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Congenital Hyperinsulinism Clinical Trial Pipeline Expands as 4+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Congenital Hyperinsulinism Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Congenital Hyperinsulinism pipeline landscape. It covers the Congenital Hyperinsulinism pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

End-stage Renal Disease Clinical Trial Pipeline Accelerates as 4+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “End-stage Renal Disease Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the End-stage Renal Disease pipeline landscape. It covers the End-stage Renal Disease pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Spinal Cord Injury Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Spinal Cord Injury Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Primary Biliary Cholangitis Pipeline Set for Major Breakthroughs by 2026 with 25+ Therapies and Strong Clinical Momentum from GlaxoSmithKline, Novartis, and CymaBay Therapeutics | DelveInsight

Primary Biliary Cholangitis Pipeline Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, Calliditas Therapeutics, Hepagene, Calliditas Therapeutics, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline, and others DelveInsight’s, “Primary … Continue reading

Blood Pressure Monitoring Devices Market to Surpass USD 6 Billion by 2032, Growing at 10.01% CAGR Amid Rising Hypertension Burden and Digital Health Adoption | DelveInsight

Blood Pressure Monitoring Devices Market Key Companies in the Blood Pressure Monitoring Devices Market are Koninklijke Philips N.V., General Electric Company, A&D Company, Hill-Rom Services Inc., American Diagnostic Corporation, Withings, Spacelabs Healthcare, Braun Healthcare, GF HEALTH PRODUCTS INC, Microlife Corporation, … Continue reading

Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight

Wilson’s Disease Market Leading Wilson’s Disease companies, including Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer,Ultragenyx Pharmaceutical, and others, are developing novel products to improve the Wilson’s Disease treatment outlook. DelveInsight’s “Wilson’s Disease Market Insights, Epidemiology, and Market Forecast – 2034” report provides … Continue reading